ReviewExperimental hematology & oncology2022
TCR engineered T cells for solid tumor immunotherapy.
Review in Experimental hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.Frontiers in immunology · 2024Pooled it
- Investigating the role of costimulatory domains in enhancing CAR-T cell persistence in TNBC.Cancer gene therapy · 2026Review
- Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses.Experimental hematology & oncology · 2026Review
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.Experimental hematology & oncology · 2026Review
- De novo engineered disulfide bond supersedes native interchain linkage to enhance TCR pairing and anti-tumor efficacy in T cell therapy.Cellular & molecular immunology · 2026Article
- Immunotherapy in Thyroid Cancer: Current Strategies and Challenges.Cancer medicine · 2026Review
- Lymphodepleting preconditioning impairs host antitumor immunity induced by adoptive T cell therapy in mouse models.Nature communications · 2026Article
- Lipid nanoparticle-mediated in vivo generation of panCAR immune cells for solid tumor immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Characteristics and developmental trajectory of clinical trials focused on tumor-infiltrating lymphocytes for cancer treatment.Cancer gene therapy · 2026Review
- Safety-first TCR-T: AI-guided specificity, base-editing to prevent mispairing, and prioritizing public neoantigens.Frontiers in immunology · 2026Article
- Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer.Experimental hematology & oncology · 2025Review
- Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies.Cell reports. Medicine · 2025Review
- Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers.Medical sciences (Basel, Switzerland) · 2025Review
- Unconventional Immunotherapies in Cancer: Opportunities and Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells.World journal of gastrointestinal oncology · 2025Review
- Advances in molecular pathology and therapy of non-small cell lung cancer.Signal transduction and targeted therapy · 2025Review
- Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.Current issues in molecular biology · 2025Review
- Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Review
- T-cell Receptor Repertoire Analysis in the Context of Transarterial Chemoembolization Synergy with Systemic Therapy for Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
T cell immunotherapy remains an attractive approach for cancer immunotherapy. T cell immunotherapy mainly employs chimeric antigen receptor (CAR)- and T cell receptor (TCR)-engineered T cells. CAR-T cell therapy has been an essential breakthrough in treating hematological malignancies. TCR-T cells can recognize antigens expressed both on cell surfaces and in intracellular compartments. Although TCR-T cells have not been approved for clinical application, a number of clinical trials have been performed, particularly for solid tumors. In this article, we summarized current TCR-T cell advances and their potential advantages for solid tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.